Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTX: Celsus Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (36)	3/21/2002 12:47:50 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 40

It is not a main reason that I invested in CLTX, but at current market condition I will take it. Miljenko [eom] Wednesday March 20, 9:15 am Eastern Time Schering To Acquire Collateral Therapeutics FRANKFURT -(Dow Jones)- German specialty pharmaceuticals company Schering AG ( SHR) said Wednesday that it plans to acquire the 88% of U.S. biotechnology company Collateral Therapeutics Inc. (CLTX) it doesn't already own, in a stock- for-stock transaction valued at $140 million. It said it will swap its own American Depositary Receipts for Collateral shares at a rate of one Schering ADR for 0.1847 Collateral shares. Schering said it expects the deal to be closed during the third quarter of 2002, pending approval from regulatory authorities and a number of Collateral shareholders. Shareholders owning 26.7% of Collateral stock have already agreed to the sale, Schering said in a statement. (This story was originally published by Dow Jones Newswires)